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Abstract
Oculopharyngeal muscular dystrophy (OPMD) is a late-onset progressive muscle disorder caused by a poly-alanine
expansion mutation in the Poly(A) Binding Protein Nuclear 1 (PABPN1). The molecular mechanisms that regulate
disease onset and progression are largely unknown. In order to identify molecular pathways that are consistently
associated with OPMD, we performed an integrated high-throughput transcriptome study in affected muscles of
OPMD animal models and patients. The ubiquitin-proteasome system (UPS) was found to be the most consistently
and significantly OPMD-deregulated pathway across species. We could correlate the association of the UPS OPMD-
deregulated genes with stages of disease progression. The expression trend of a subset of these genes is age-
associated and therefore, marks the late onset of the disease, and a second group with expression trends relating
to disease-progression. We demonstrate a correlation between expression trends and entrapment into PABPN1
insoluble aggregates of OPMD-deregulated E3 ligases. We also show that manipulations of proteasome and
immunoproteasome activity specifically affect the accumulation and aggregation of mutant PABPN1. We suggest
that the natural decrease in proteasome expression and its activity during muscle aging contributes to the onset of
the disease.
Background
Oculopharyngeal muscular dystrophy (OPMD) is a late-
onset progressive muscle disorder for which the under-
lying molecular mechanisms are largely unknown. This
autosomal dominant muscular dystrophy has an esti-
mated prevalence of 1 in 100,000 worldwide [1]. A
higher prevalence has been reported in the Jewish Cau-
casian and French-Canadian populations (1 in 600 and 1
in 1,000, respectively) [2,3]. OPMD is caused by expan-
sion of a homopolymeric alanine (Ala) stretch at the
N-terminus of the Poly(A) Binding Protein Nuclear 1
(PABPN1) by two to seven additional Ala residues [4].
Although PABPN1 is ubiquitously expressed, the clinical
and pathological features of OPMD are restricted to a
subset of skeletal muscles, causing progressive ptosis,
dysphagia, and limb muscle weakness. In affected mus-
cles, the expanded PABPN1 (expPABPN1) accumulates
in intranuclear inclusions (INI) [5]. Animal models for
OPMD were generated in Drosophila, mice and Caenor-
habditis elegans with a muscle-specific expression of
expPABPN1 [6-8]. These models recapitulate INI forma-
tion and progressive muscle weakness in OPMD, and a
correlation between INI formation and muscle weakness
has been reported [6-8]. In these OPMD models protein
disaggregation approaches attenuate muscle symptoms
[8-10]. So far, however, the molecular mechanisms that
are associated with OPMD onset and progression are
not known. Previously, we performed transcriptome
analysis on skeletal muscles from a mouse model of
OPMD and found massive gene deregulation, which was
reflected by a broad spectrum of altered cellular path-
ways [11]. We found an association of transcriptional
changes with muscle atrophy [11]. Muscle atrophy was
recently reported in homozygous OPMD patients [2].
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However, the vast majority of OPMD patients are het-
erozygous and muscle atrophy is not a common patho-
logical characteristic of the disease in its early stages.
Importantly, a mouse model with low and constitutive
expPABPN1 expression exhibits minor muscle defects
without muscle atrophy [12]. Hino et al. [12] suggested
that the extent of muscle symptoms caused by
expPABPN1 depends on the expression level. Therefore,
it is not known whether the massive transcriptional
changes in affected muscles of the A17.1 OPMD model
[11] are due to the high over-expression of expPABPN1
or if they are common with transcriptional changes in
OPMD patients.
We have generated microarrays of OPMD carriers at
pre-symptomatic and symptomatic stages. Since OPMD
is categorized as a rare disorder in Western countries,
limited patient material is an obstacle in reaching con-
clusive results. Therefore, we performed a cross-species
transcriptome study by integrating transcriptome data
from Drosophila and mouse models and heterozygous
OPMD patients. We hypothesized that OPMD-asso-
ciated molecular mechanisms would be consistently
deregulated across species. As bioinformatics analyses
of gene expression are biased by the computational
approaches [13], here we integrated three computational
methods to obtain a higher degree of confidence and
reproducibility. The ubiquitin-proteasome system (UPS)
was identified as the most significant and consistent
OPMD-deregulated pathway across species.
Results
Genome-wide expression profiles from the Drosophila
and mouse OPMD models [6,11] were integrated with
the expression profiles of heterozygous OPMD carriers
(datasets are described in Additional file 1 Table S1 and
Table S2). Genes that are differentially expressed between
OPMD and controls (OPMD-deregulated) were identi-
fied using limma model in R [14]. To identify the most
prominent and consistent feature across all species, com-
parative pathway analysis was performed using three
computational methods (Additional file 1 Figure S1). In
literature-aided analyses [15], the term ‘ubiquitination’
was found to be the most strongly associated biomedical
concept with OPMD-deregulated genes (Table 1 and
Additional file 1 Table S3). A regression-based analysis
using global test (GT) [16], and an enrichment method
using the Database for Annotation, Visualization, and
Integrated Discovery (DAVID) [17,18] revealed highly
significant deregulation of ubiquitin-proteasome system
(UPS)-related GO (Gene Ontology) categories and KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathways
across species (Table 1).
To evaluate the level of concordance between the animal
models and OPMD patients, gene overlap between the
OPMD-deregulated UPS genes was determined. Homolo-
gous genes were annotated using the HomoloGene and
Inparanoid databases (see Methods). In total, 16%, 32%
and 25% of the genes annotated to the UPS were identi-
fied as OPMD-deregulated in Drosophila, mice and
humans, respectively (Figure 1A). More than half of the
OPMD-deregulated genes in Drosophila (59%) over-
lapped with their mouse or human homologous genes,
and close to half (45% and 51%) overlapped between
mouse and human genes, respectively (Figure 1A). The
similarity of deregulation direction across species was
demonstrated for 14 genes, for which probes were found
in all organisms (Figure 1B). Similar transcriptional
changes were found for 13 homologous genes in mouse
and human datasets. Among those, eight genes showed
similar changes in Drosophila. These results show the
consistent UPS deregulation in OPMD.
To validate the microarray analyses, quantitative RT-
PCR (Q-PCR) was performed on 19 OPMD-deregulated
UPS genes from mice. Genes were selected based on
P-value and >1.3-fold change criteria. For 17/19 genes
(89%), Q-PCR results confirmed the results of the micro-
array analyses (Additional file 1 Figure S2). This demon-
strates the reproducibility and validity of the microarray
statistical analyses.
In the A17.1 mouse model, muscle atrophy is more
prominent in fast glycolytic fibers (quadriceps) as com-
pared with slow oxidative fibers (soleus) [11]. Since
muscle atrophy is regulated by the UPS [19-21], we ana-
lyzed the muscle-type specific expression of 10 OPMD-
deregulated UPS genes in order to identify a correlation
with muscle atrophy. Q-PCR was performed on RNA
isolated from quadriceps and soleus of six-week-old
A17.1 and control (Friend Virus B inbred (FVB)) mice.
The majority (8 out of 10) of genes showed no fiber-
type specificity (Figure 1C). Only the deregulation of
Trim63 [11] and Ube3b were specific to fast glycolytic
fibers (Figure 1C). This suggests that the majority of
OPMD-deregulated UPS genes are not associated with
muscle atrophy in the A17.1 mouse.
The UPS involves an enzymatic cascade of ubiquitina-
tion and degradation steps. The ubiquitination steps start
with ubiquitin activation, which requires the ubiquitin-
activating enzyme (E1) and ubiquitin (Ub). This process
results in the binding of Ub to the E2-conjugating enzyme.
In a subsequent step the target protein is ubiquitinated
with Ub-E2 and E3-ligase complexes, which ensures target
specificity. Poly-ubiquitinated proteins are subjected to
degradation. This step is employed by the deubiquitinating
enzymes (DUBs) and the proteasome [22,23]. Deregulation
of genes involved in the ubiquitin activation step was not
found to be consistent between OPMD and the models
(Figure 2 and Table 2). Ubiquitin up-regulation was pre-
viously reported in a non-muscle cell model for OPMD
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[24]. Our study identified only one ubiquitin-encoding
gene to be up regulated in mouse and human genomes,
but these deregulated genes were not consistent across
species. The E2-conjugating enzymes were significantly
deregulated in Drosophila and mouse genomes, whereas
in humans, the P-value for these enzymes was not signifi-
cant. This suggests a weak association of E2 deregulation
with OPMD (Figure 2 and Table 2). In contrast, consistent
deregulation was found for E3-ligases, DUBs, and protea-
some (Figure 2 and Table 2). The significance of this
Table 1 Deregulation of ubiquitin-proteasome system (UPS) in OPMD in Drosophila, human and mouse
Drosophilaa Mouse Human
Literature Analysis
Ubiquitination # 2 # 1 # 1
GO Categories
Ubiquitin-dependent Protein Catabolic Process 2.81E-04 2.27E-07 1.22E-03
Protein Ubiquitination 7.57E-03 1.88E-05 9.24E-04
Proteasomal Protein Catabolic Process 6.51E-03 2.23E-07 1.86E-03
KEGG Pathways
Ubiquitin Mediated Proteolysis 2.03E-03 8.25E-08 1.52E-03
Proteasome 2.15E-04 1.37E-07 9.27E-03
For Drosophila and mouse P-values are derived from the combined analysis of the three time points using global test, where age was included as a confounder
in the model.
Figure 1 Cross species deregulation of ubiquitin-proteasome in OPMD. A) Venn-diagram displaying the overlap in OPMD-deregulated
genes in UPS across species. In mice and Drosophila, OPMD-deregulated genes should be consistently deregulated in at least two time points.
The total number of genes in UPS is indicated in italics. The list of OPMD-deregulated UPS genes is in Additional File 2. B) Transcriptional
changes of selected genes in UPS in different organisms. Histograms display the log2(ratio) of the measured expression values in Drosophila
(white bars), mice (gray bars), and humans (black bars). Significant changes with the adjusted P < 0.05 are indicated by *. C) RT Q-PCR validation
of selected deregulated genes in UPS was carried out on quadriceps (i) and soleus (ii) muscles of six-week-old mice. Histograms show the
measured expression values for A17.1 and FVB mice using Q-PCR. Significant changes of measured expression values of A17.1 mice as compared
to FVB with the P < 0.05 are indicated by *.
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strong association was further evaluated by gene-overlap
of homologous genes in humans and mice (Table 2). The
gene overlap between mice and humans was found to be
significant for all these three UPS components (P-values
are 6.64E-08 for E3-ligases, 1.37E-02 for DUBs and 1.70E-
02 for the proteasome). Overall, this analysis demonstrates
consistent deregulation of E3-ligases, DUBs and protea-
some across species.
OPMD is characterized by a late onset and a slow pro-
gression of muscle weaknesses [4,25]. Progressive muscle
weakness has also been reported in the mouse model [7].
In 6-week-old mice symptoms were not detected, while
muscle weakness was present in 18-week-old mice and
was more pronounced by 26 weeks [7]. If changes in
expression levels are associated with disease onset and
progression, a correlation between age and expression
levels should be expected. A linear regression model was
applied to the mouse UPS genes at three time points in
order to identify genes that their expression trends are
progressively changed. 80% of the OPMD-deregulated
UPS genes show a progressive trend, which is age-
associated (N = 171/217, Additional file 1 Figure S3A,
examples for progressive expression trends are shown in
Figure 3Ai). To identify genes with expression trends
that are specific to the disease a regression model that
combines age and disease features was applied. In 30%
of the age-associated OPMD-deregulated UPS genes
(N = 50, Figure S3B) the progression trends significantly
Figure 2 OPMD deregulated genes in the UPS. Pie charts show the relative distribution of the UPS units (light colors) and OPMD-deregulated
genes (dark colors) per organism. Numbers indicate the percentage of OPMD-deregulation.
Table 2 The distribution of OPMD-deregulated genes in UPS functional units and protein degradation categories
Drosophila Mouse Human Overlap mouse vs.
human
# Total
Genes
% D.E.
Genes
PValue
(FDR)
# Total
Genes
% D.E.
Genes
P-Value
(FDR)
# Total
Genes
% D.E.
Genes
P-Value
(FDR)
# D.E.
Genes
% D.E.
Genes
Ubiquitin 2 50.00 4.18E-05 3 11.11 1.28E-01 3 33.33 1.19E-01 0 00.00
E1 Ubiquitin
Activation
4 16.67 1.24E-01 7 04.76 7.29E-02 7 14.29 7.94E-02 0 00.00
E2 Ubiquitin
Conjugation
22 13.64 9.19E-06 33 44.42 1.51E-08 34 23.53 7.31E-02 3 37.50
E3 Ubiquitin
Ligase
249 13.99 1.92E-04 526 29.58 1.64E-08 586 24.74 4.35E-03 69 47.59
Deubiquitination
(DUB)
35 20.00 1.63E-05 72 45.83 1.48E-08 75 24.00 3.15E-02 13 72.22
¥ Proteasome 47 29.79 2.15E-04 37 36.94 1.37E-07 37 51.35 9.27E-03 11 57.90
¥ Autophagy 16 25.00 1.07E-03 39 30.77 8.13E-08 32 18.75 1.37E-02 1 16.67
¥Lysosome 60 5.00 1.64E-02 75 25.33 6.06E-03 73 24.68 1.54E-02 6 33.33
The number of annotated genes per unit, the percentage of OPMD-deregulated (D.E.) genes and P-values are indicated per organism. For Drosophila and mouse
statistics is generated in combined datasets from three time points. The overlap in OPMD-deregulated genes between humans and mice and the percentage of
deregulated genes in human D.E. genes are indicated. Protein degradation machineries are depicted by ¥.
Anvar et al. Skeletal Muscle 2011, 1:15
http://www.skeletalmusclejournal.com/content/1/1/15
Page 4 of 14
Figure 3 Progressive changes in UPS gene expression. Progression trends for selected genes in mice (i) and humans (ii). Expression values
were normalized to six-week-old WT in mice, and to young healthy controls (19 years old on average) in humans. P-values demonstrate the
significance of differences in expression trends between controls and OPMD samples. A) The age-associated progression trend is indicated by
P-value >0.05. B) The genotype-specific progression trend is indicated by P-values <0.05. SD represents variations in mice (6 weeks N = 5 and
26 weeks N = 6) and in humans (expPABPN1 carriers N = 4 and controls N = 5). C) RT Q-PCR validation of selected deregulated genes in UPS
was carried out on skeletal muscles of 6-week-old and 26-week-old mice. Histograms show the log2(ratio) of the measured expression values
using microarray and Q-PCR. Significant changes with the P <0.05 are indicated by *.
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(P-value <0.05) differed between A17.1 and the wild-type
(WT) controls (examples for progressive expression trends
are shown in Figure 3Bi). The genes with disease-specific
progression can be used to mark disease progression and
could contribute to disease onset and progression. The
group of genes whose expression changes with age inde-
pendent from the disease, however, may contribute to the
late onset of the disease.
The vast majority of OPMD-deregulated UPS genes,
which exhibit progressive expression profiles encode for
E3-ligases (Additional file 1 Figure S3). Expression
trends for selected E3-ligases are presented in Figure 3.
Confirmation of the analysis in mice was carried out on
the human homologues (Figure 3). The age-associated
expression trends were similar between A17.1 and WT
in mice and between controls and expPABPN1 carriers
at pre-symptomatic and symptomatic stages in humans
(Figure 3A). The progression trends did not significantly
differ between genotypes (P-value >0.05). In contrast,
for those genes with expression trends associated with
age and disease the expression trends of controls signifi-
cantly differed from those of OPMD subjects (Figure 3B,
P-value <0.05). Validation of progression analysis was
performed by Q-PCR analysis of RNA from 6- and
26-week-old mice (Figure 3C). The Q-PCR results
demonstrate the reproducibility and validity of the
microarray progression analysis.
In the progression analysis some differences between
humans and mice were noted. The progression of Trim63
is mouse-specific, whereas the expression of the human
TRIM63 is not age-associated or OPMD-deregulated
(Figure 3B). Asb11 is down regulated in mice while it is up
regulated in humans (Figure 3A). The expression trend of
Socs4 in mice is negative while in humans it is positive
(Figure 3B). These discrepancies could reflect differences
between the two organisms or between the heterozygous
and the high over-expression situation.
Expression of expPABPN1 leads to INI formation in
affected muscles [7,11]. Previous studies have demon-
strated that ubiquitin and proteasome proteins co-localize
with INI in affected muscles [26] and in non-muscle
cells [24,27]. Since INI formation is a hallmark of OPMD,
we studied whether the expression profiles of OPMD-
deregulated E3-ligases correlate with their entrapment
with expPABPN1 in INI. Co-localization was analyzed
with an immunofluorescence procedure in C2C12 myo-
tubes expressing expPABPN1 fused to yellow fluorescent
protein (YFP). From the E3-ligases encoding genes that
showed an association with disease onset or progression
(Figure 3), five were selected for co-localization studies
using specific antibodies recognizing single proteins at the
appropriate molecular weights. All five proteins showed
nuclear localization in myotubes and co-localized with
expPABPN1 in INI (Figure 4). Arih1, Asb11 and Ddb1
co-localized with all sizes of INI structures (Figure 4A)
while the co-localization of Trim63 and Fbxo32 proteins
were only evident for larger INI structures (Figure 4B,
highlighted in boxes). This suggests a correlation between
changes in expression trends and temporal entrapment in
INI.
The proteasome is composed of core and regulatory
subunits. Genes encoding for the proteasome core subu-
nit were prominently down regulated in mice and
humans (66% and 75%, respectively), while no preference
in deregulation direction was found for the regulatory
subunit (Figure 5A andAdditional file 1 Table S5).
Down-regulation of the proteasome could affect protein
degradation and, hence, protein accumulation. In C2C12
myoblasts that were treated with low concentrations
(5 μM) of the proteasome inhibitor MG132, the accumu-
lation of expPABPN1 was significantly higher as com-
pared with mock-treated cells (Figure 5B). Similarly,
treatment with the DUB inhibitor, PR619, also caused
expPABPN1 accumulation (Figure 5B). High nuclear
accumulation of expPABPN1, which accompanies INI
formation, was consistently measured in MG132-treated
cells using a cell-based intensity fluorescence quantifica-
tion assay (Figure 5C). Thus, reduced proteasome and
DUB activities in muscle cells promoted expPABPN1
accumulation and INI formation in muscle cells. How-
ever, expPABPN1 accumulation stimulated by protea-
some inhibition is not specific to muscle cells [24].
In addition to the proteasome, the lysosome and the
autophagy machineries can also facilitate protein catabo-
lism. To evaluate whether one of these machineries could
also regulate expPABPN1 protein accumulation, the sig-
nificance of deregulation in OPMD was analyzed. Overall,
deregulation of lysosome and autophagy were not consis-
tent across species. The lysosome KEGG pathway was
evaluated as significantly deregulated in OPMD across
species by GT but not by DAVID analysis (Table 2). How-
ever, in the literature-aided analysis, only a low level of
association was found between OPMD-deregulated genes
and lysosome in Drosophila and humans (ranked at posi-
tions 196 and 789, respectively), while no association was
found in mice. Similarly, the autophagy KEGG pathway
was significant across species based on GT but not on
DAVID analysis (Table 2). In the literature-aided analysis,
autophagy was ranked 12 in mice, but a lower priority
(ranked 136 and 154) was found in Drosophila and
humans, respectively. Furthermore, the OPMD-deregu-
lated gene overlap between mice and humans was not sig-
nificant for either lysosome or autophagy pathways (P-
values: 5.37E-01 and 3.70E-01, respectively). This is in
sharp contrast to the consistent proteasome deregulation
found across species. This indicates that, from the protein
degradation pathways, only proteasome deregulation is
consistently associated with OPMD across species. From
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Figure 4 Co-localization of selected E3 ligases with INI in C2C12 myotubes expressing YFP-Ala16PABPN1. Immunostaining of E3-ligases
was visualized with Alexa-594 secondary antibodies. Co-localization with expPABPN1 in myotubes is demonstrated in the merge image. A 2.5X
magnification of nuclei containing expPABPN1 aggregates is highlighted in a box. A) Arih1, Asb11 and Ddb1 E3 ligases show consistent
co-localization with aggregated YFP-Ala16-PABPN1. B) Trim63 and Fbxo32 E3 ligases show progressively more co-localization with YFP-Ala16-
PABPN1 as INI size increases. Scale bar is 10 μm.
Anvar et al. Skeletal Muscle 2011, 1:15
http://www.skeletalmusclejournal.com/content/1/1/15
Page 7 of 14
Figure 5 The effect of altered proteasome activity on expPABPN1 accumulation and aggregation. A) Substantial deregulation of
proteasome and immunoproteasome encoding genes in mice and humans. Down-regulation (green) is more pronounced in the core subunit
of the proteasome. Immunoproteasome shows consistent up-regulation (red) in both organisms. B) Western blot analysis of YFP-Ala16-PABPN1
transfected C2C12 cells that were treated with 5 μM MG132 or 5 nM PR619. Control cells were treated with DMSO. C) Images show YFP-Ala16-
PABPN1 localization in C2C12 after mock-treatment (DMSO), 5 μM MG132 or 5 U/ml IFNg. Scale bar equals 10 μm. Histograms show the
integrated intensity of YFP-Ala16-PABPN1 (i) or Histone4-CFP (control) (ii), and the percentage of cells with INI in YFP-Ala16-PABPN1 expressing
cells (iii). Averages represent 509, 773 and 476 cells for DMSO, MG132 and IFNg, respectively. Significant difference between treatments is
reflected by P-values.
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this analysis we cannot exclude lysosome or autophagy
deregulation in OPMD, but the lack of consistency across
species and in three bioinformatics analyses suggests a
smaller contribution as compared with the proteasome.
In contrast to the down-regulation of genes in the core-
subunit, the expression of genes encoding for the immu-
noproteasome subunit (the cytokine-induced proteasome)
was consistently elevated in OPMD (Figure 5A). The
immunoproteasome was initially identified in cells of the
immune system after cytokine induction, which is involved
in MHC-class-I antigen presentation [28]. However, the
accumulation of cytokine-induced proteasome proteins
was also found in aging skeletal muscle cells [29]. Treat-
ment of C2C12 myoblasts with IFNg, an inducer of immu-
noproteasome activity [30], led to a significant reduction
in nuclear expPABPN1 accumulation (Figure 5C, Ci) and
INI formation (Figure 5Ciii). In contrast to expPABPN1,
accumulation of Histone4, which is also a nuclear protein,
was not significantly affected by manipulation of protea-
some activity (Figure 5Cii). This suggests that the accumu-
lation of expPABPN1, but not of Histone4, is receptive to
the level of proteasome and immunoproteasome activity.
Together, our results demonstrate that the UPS degrada-
tion machinery regulates expPABPN1 accumulation.
Discussion
UPS is a cellular regulator of homeostasis and is involved
in a wide spectrum of human diseases including cancer,
neurodegenerative disorders and diabetes [31-35]. Dereg-
ulation of UPS has been reported for myotonic dystrophy
type 1 [36] and muscle atrophy in mice [19-21]. In addi-
tion, altered UPS activity has been associated with muscle
aging [33,37]. Together these studies suggest that muscle
cell function is tightly regulated by the UPS. In this
study, we identified the UPS as the most consistently and
significantly deregulated cellular machinery in OPMD
animal models and patients. Transcriptome studies in
non-muscle cells expressing expPABPN1 did not reveal
substantial and predominant deregulation of UPS genes
[38]. This indicates that the effect of expPABPN1 on UPS
deregulation is specific to muscle cells. Since PABPN1 is
ubiquitously expressed in every cell but the phenotype is
limited to muscle cells this suggests that UPS deregula-
tion confers the muscle-specific pathogenesis of OPMD.
From six UPS components, only E3-ligases, DUBs and
the proteasome were found to be consistently and promi-
nently deregulated in OPMD across species. Relevant to
OPMD proteasome activity is reduced during muscle
aging [29,33,37], and is associated with transcriptional
deregulation of proteasomal genes [37]. In the analysis of
expression trends the expression of 89% of the OPMD-
deregulated proteasome genes were found to be age-
associated. This suggests that the natural decrease in pro-
teasome expression during muscle aging can contribute
to the late onset of the disease. Our analysis revealed that
the core subunit of the proteasome is the only UPS subu-
nit that was consistently down-regulated which can cause
reduced activity of the proteasome machinery. In a recent
study, we found that expression of expPABPN1 in myo-
tubes leads to down-regulation of proteasome-encoding
genes, and causing the accumulation of expPABPN1 pro-
tein (unpublished data). However, proteasome regulation
of expPABPN1 accumulation and INI formation is not
specific to muscle cells [24]. Since in patients INI are
formed only in muscle cells, this suggests that proteasome
down-regulation during muscle aging triggers expPABPN1
accumulation. In turn, accumulation of expPABPN1 leads
to extensive proteasome down-regulation in OPMD
(Figure 6). This feed-forward model could justify the mus-
cle-specific INI formation and the late onset in OPMD.
Hypothesizing that changes in expression levels could
reflect pathological changes in disease status we have stu-
died the correlation between transcriptional changes of
OPMD-deregulated UPS genes and age. Noticeably, the
expression of the vast majority of the OPMD-deregulated
UPS genes is progressed during normal muscle aging. This
suggests that transcriptional changes of these genes are
associated with disease onset. The expression trends of a
subset of these genes showed disease-specific progression.
Among those, Trim63 and Fbxo32 exhibited disease pro-
gression in mice. Both genes are known for regulating
muscle atrophy in mice [19-21]. In the OPMD mouse
model, muscle atrophy in exhibited only in fast muscle
glycolytic fibres and Trim63 expression correlates with
muscle atrophy in A17.1 [11]. However, the majority of
the OPMD-deregulated UPS genes did not show fibre-
type specific expression. This could suggest that UPS
deregulation in OPMD has a broader pathological effect
than muscle atrophy. Indeed, in affected muscles of
OPMD patients, atrophy may be evident only at a later
stage of disease progression; although a high degree of
consistency between expression trends in mice and
humans was found for the majority of the genes analyzed
in this study. Trim63 deregulation and progression is
probably mouse-specific, as OPMD-deregulation or pro-
gression was not found in humans. Fbxo32, however, was
consistently deregulated in both organisms and, therefore,
can be a candidate for regulating disease progression and
muscle atrophy in humans. After mining the NCBI dataset
for tissue-specific expression (Unigene Hs.352183, Build
No. 228 released 2010), Asb11 was noted for its specific
expression in skeletal muscles. Since Asb11 is consistently
OPMD-deregulated in humans and mice, and its expres-
sion trend is associated with disease onset it could repre-
sent a relevant candidate for functional genomic studies.
This shows that cross-species transcriptome and progres-
sion analyses can be used to identify target molecules for
future studies.
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OPMD is characterized by INI formation. The role of
INIs in disease pathogenesis is unknown. Previous stu-
dies have shown that many genes whose expression is
deregulated by expPABPN1 are found to be co-localized
in INI [38]. Components of the proteasome, which is
OPMD-deregulated, also co-localize in INI [24,27]. We
also found that many of the OPMD deregulated E3-
ligases are entrapped in INI. Moreover, we demonstrate
a correlation between temporal changes in expression
levels and sequential entrapment in INI. Together these
studies suggest that entrapment in INI could lead to
transcriptional deregulation. It is possible that protein
entrapment in INI affects gene expression through a
compensatory mechanism resulting in altered transcrip-
tional profiles.
Conclusions
In this study, we combined expression datasets from
three organisms and disease models with different bioin-
formatics analyses in a single study. This allowed us to
identify with high confidence the UPS as the most pre-
dominantly deregulated cellular pathway in OPMD. This
approach differs from most microarray studies where
results are derived from a single computational analysis
performed on a single organism. We show that with this
combined bioinformatics approach the list of deregu-
lated pathways can be prioritized with high confidence.
This approach can facilitate studies with complex biolo-
gical situations and massive gene deregulation, such as
late onset disorders and rare-diseases.
The most significant and novel finding in this study is
the substantial and cross-species consistent deregulation of
the UPS in OPMD. We propose that protein entrapment
in PABPN1 aggregates is associated with a substantial tran-
scriptional deregulation of the UPS that, in turn, leads to
disruption of homeostasis in skeletal muscles. By taking
advantage of the detailed analysis of gene expression trends
and muscle-expression, we predict that candidate genes
can be selected for functional genomic studies which ulti-
mately lead to the identification of OPMD pathogenesis.
Methods
Generation of microarray datasets
Drosophila and mouse microarray datasets have pre-
viously been published [10,11]. Human quadricep muscle
samples were collected with the needle or by an open
surgical procedure from OPMD patients and family
members as well as from anonymous age-matching
healthy individuals that gave informed consent. The pre-
sence of expansion mutation in PABPN1 in OPMD
patients and pre-symptomatic individuals was determined
with sequencing. Bergstrom needle biopsies from the
(pre)symptomatic patients were approved by the ethical
committee. Total RNA was extracted from skeletal mus-
cles using RNAease Bee (Amsbio, Abingdon, United
Kingdom) according to the manufacturer’s instructions.
RNA integration number (RIN) was determined with
RNA 6000 Nano (Agilent Technologies Amstelveen, The
Netherland). RNA with RIN >7 were used for subsequent
steps. RNA labeling was performed with the Illumina®
TotalPrep RNA Amplification kit (Ambion, Austin, TX,
United States) according to the manufacturer’s protocol,
and subsequently was hybridized to Illumina Human v3
Bead arrays. The generated microarray datasets are
Figure 6 A model for the involvement of UPS in OPMD disease pathology. In muscle, age-associated proteasome down-regulation affects
expPABPN1 protein accumulation. Elevated expPABPN1 accumulation affects proteasome deregulation during disease onset. Expression profiles
of E3-ligases can be sued to separate disease onset from progression.
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deposited and publicly available at GEO repository. GEO
accession numbers for mouse and human microarray
datasets are GSE26604 and GSE26605, respectively.
Data processing and statistical analysis
Microarray measurements were normalized using the
quantile method [39]. Each organism and time point
was normalized separately. The quality of the data was
assessed by principal component analysis.
For Drosophila and mice, genes differentially
expressed between OPMD and control subjects were
identified at each time point by applying a hierarchical
linear model using the limma package in R [14]. Human
subjects were grouped into healthy, pre-symptomatic
and symptomatic subjects. P-value cut-offs of 0.05 after
multiple-testing correction using the method of Benja-
mini and Hochberg (False Discovery Rate (FDR) were
applied to the Drosophila and mouse samples and, due
to higher inter-individual variation, a nominal P-value
cut-off of 0.05 was used for human samples) were used.
This resulted in lists of OPMD-deregulated genes for
each time point and organism. Probe annotation was
done using the indac (Drosophila), illuminaMousev1Bea-
dID (mouse), and illuminaHumanv3BeadID (human) R
packages. The OPMD significantly deregulated genes in
the UPS from human and mouse datasets are listed in
Additional File 2.
Pathway analyses
GT [16] was used to identify significant associations
between GO categories or KEGG pathways and OPMD,
while including age as a confounder (Drosophila and mice
only). Gene sets with multiple testing adjusted (Holm’s
method) P-value <0.05 were selected as significant.
DAVID, a functional annotation clustering tool [17,18],
was applied on a list of OPMD-deregulated genes and
pathway redundancy was removed by clustering similar
GO categories and pathways. In addition, biomedical con-
cepts that are associated with OPMD-deregulated genes
were identified using a literature-aided mapping tool, Anni
2.0 [15]. The procedure was performed for each organism
separately. Cross-species analyses were carried out on a
group of homologous genes. Drosophila homologues of
mouse and human genes were annotated using Homolo-
Gene http://www.ncbi.nlm.nih.gov/homologene and
Inparanoid http://inparanoid.sbc.su.se online databases.
Integration of three time-points in Drosophila and mice
(Additional file 1 Table S1) were used to identify OPMD-
deregulated pathways across species (Figure 1). A recent
annotation of E3 ligases [40] was used to identify OPMD-
deregulated E3 ligases. The annotation for all other UPS
components is extracted from KEGG. Since the annota-
tion for genes encoding for lysosome is not available in R
packages, we have extracted the annotation from KEGG
website and integrated it into our pathway analyses.
Progression studies
For testing the significance of the association of expres-
sion trends of OPMD-deregulated genes with age, using
limma model in R [14], a linear regression model
(expression ~ aOPMD + bAGE + δ(OPMD × AGE) + ε)
was applied on combined datasets from 6- and 26-week-
old mice. Age-associated changes were identified as
those with b significantly different from zero. OPMD-
and age-associated changes were defined as those with δ
significantly different from zero. To determine whether
the expression profiles of individual genes significantly
differ between controls and OPMD P-values are FDR-
corrected with the cut-off threshold of 0.05.
Quantitative RT-PCR analysis
Primers for Q-PCR validation were designed in the
sequence surrounding the Illumina probe location using
Primer 3 plus program. RT-QPCR was performed
according to the procedure in Trollet et al. [11]. The
list of primers is provided in Table 3.
Cell culture and transfection
C2C12 cells were used for transient transfection experi-
ments. C2C12 cells were cultured in DMEM containing
20% fetal calf serum. Prior to transfection, cells were
seeded on glass. Transfection was carried out in 80%
cell confluence with Lipofectamine™ 2000 (Invitrogen,
Breda, The Netherlands) according to the manufac-
turer’s protocol. Plasmids used for transfection are YFP-
Ala16-PABPN1 and Histone4-CFP. For the proteasome
modification treatments, cells were treated 16 hours
after transfection with DMSO (1:1000), 5 μM MG132
(Sigma-Aldrich St. Louis, MO, UnitedStates), or 5 U/ml
IFNg (HyCult Biotech Uden, The Netherlands) for
20 hours.
Protein detection and Imaging
For immunocytochemistry, 16 hours post-transfection
with YFP-Ala16-PABPN1, C2C12 cells were incubated
with fusion medium (DMEM supplemented with 2.5%
horse serum) for two days, and immunocytochemistry
was performed after a short fixation [41] followed by a
15-minute incubation with 1% Triton X100, during
which PABPN1 aggregates remain intact. Following anti-
body incubations, preparations were mounted in Citi-
fluor (Agar Scientific Essex, United Kingdom)
containing 400 μg/ml of DAPI (Sigma-Aldrich). Immu-
nofluorescent specimens were examined with a fluores-
cence microscope (Leica DM RXA Vienna, Austria), 63×
and 100× lens NA 1.4 plan Apo objective. Integrated
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intensity was measured with ImageJ http://rsbweb.nih.
gov/ij/, and intensity values were corrected for
background.
Antibodies used in this study are: goat anti-Asb-11
(K16) (1:1,000) Santa Cruz Biotechnology Santa Cruz,
CA, United States; rabbit anti-atrogin-1 (1:1,000) ECM
Biosciences Versailles, KY, United States; rabbit anti-
Murf1 (1:1000) ECM Biosciences; goat anti-DDB1
(1:1000) Abcam Cambridge, United Kingdom; mouse
anti-Flag (1:2000) Sigma-Aldrich; rabbit anti-Desmin
MP Biomedicals (Solon, OH, United States). Alexa-Fluor
594 conjugated secondary (Invitrogen) or IRDye 680LT
and 800CW conjugated secondaries (Licor Biosciences
St Lincoln, NE, United States) were used for detection
of first antibody.
Additional material
Additional file 1: Supplementary figures and tables. Table S1:
Overview of genome-wide transcriptome microarray datasets of
Drosophila and mouse OPMD models and muscle biopsies of OPMD
patients. Table S2: Overview of muscle biopsies of OPMD patients and
controls. Table S3: Literature-aided analysis of the association of
biomedical concepts with OPMD-deregulated genes. Table S4: Spreading
of OPMD-deregulation in UPS over the functional components and sub-
classes of E3-ligases. Table S5: Direction of OPMD-deregulation over the
functional components of UPS that are significantly deregulated in all
organisms. Figure S1: Integrated cross-species high-throughput
transcriptome study. Figure S2: Validation of expression level of selected
genes from the pool of UPS OPMD-deregulated genes on the skeletal
muscle of six-week-old OPMD mice, normalized to WT. Figure S3:
Temporal changes in UPS gene expression.
Additional file 2: A list of deregulated UPS genes in mouse and
human datasets. This additional file contains t-statistics (fold change
and P-value) for genes within the ubiquitin-proteasome pathway, in
human and mouse datasets. The t-statistics represent the association of
the gene expression profiles to OPMD.
Abbreviations
Ala: alanine; GO: gene ontology; GT: global test.
Acknowledgements
This work was supported by grants from European Commission (PolyALA
LSHM-CT-2005018675) and Muscular Dystrophy Association (68016) to S.M.
M., the Centre for Medical Systems Biology within the framework of the
Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific
Research (NWO), the CNRS (UPR1142), the ANR Genopat (ANR-09-GENO-025-
01), the FRM ("Equipe FRM 2007” N°DEQ20071210560), and the European
Commission (PolyALA LSHM-CT-2005-018675) to M.S. The funders had no
role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Author details
1Center for Human and Clinical Genetics, Leiden University Medical Center,
P.O. Box 9600, 2300 RC Leiden, the Netherlands. 2Radboud University
Nijmegen Medical Centre, Department of Neurology, Nijmegen, the
Netherlands. 3Department of Anaesthesia, Canisius-Wilhelmina Hospital,
Nijmegen, the Netherlands. 4Neuromuscular Research Unit and Department
of Neurology, University of Copenhagen, Rigs Hospitalet, Denmark. 5School
of Biological Sciences, Royal Holloway - University of London, Surrey, TW20
0EX, UK. 6INSERM U974, UMR 7215 CNRS, Institut de Myologie, UM 76
Université Pierre et Marie Curie, Paris, France. 7Institut de Genetique
Humaine, CNRS UPR1142, 141 rue de la Cardonille, 34396 Montpellier Cedex
5, France.
Authors’ contributions
SYA and AV performed the bioinformatics studies. AV and VR performed the
molecular genetics studies. Biological samples were provided by BS, BE, MS,
Table 3 The list of primers used for quantitative RT_PCR analysis
Genes Probe FW Primer Sequence RV Primer Sequence
Arih1 6900025 GAGAAGGATGGCGGTTGTAA ATCTCTTGCTGCCTTTGCAT
Arih2 2810025 AGCCTAACTCCCCCTTGGTA ACCACTGAGGGTGCAAAAAC
Ate1 6940722 CAAAGTGATTCTACTGTGGCTGA ACGAAAATCTCCAATGCAGTC
Cul7 3360114 CGGGACTATGCGGTGATACT GTGGGTTCGTCTGTGGTCTT
Psme3 2810537 GCGAAGGTCAAACCCATAGA GAAAGTGATGCATCCCAGGT
Rbx1 2340047 TTGAGGCCAGCCTACAGAGT AGGAAAACTCCCCTGAAGGA
Skp1a 2450102 TGCAGCTGGGCTCTCTTAAT GTTTCTCCACCTGGGAACAA
Uchl1 1230066 CCTGTCCCTTCAGTTCCTCA GATTAACCCCGAGATGCTGA
Huwe1 106840041 GCTGCATTGAGACTTGAAACC TCCACAACACAGATGCCAAT
Tbl1x 6400524 ATTTTCCCCCTCCCCTAATC GAGCCTGTTCTGGATGGAAA
Ube4b 3610154 GCTGGAGTGGATCAGGACTC TGGTAAGGTCAAACCCCAAA
Ube2o 2190040 CGGTGAGCACATTACAGCTC GCATCATGCTTTGGCTTTTT
Usp47 100940601 GAATGCTTGTAAAGTCCCGTTT CTAGCACGCTCTGCAATGAA
Ppp2cb 5570593 ACTGCTACCGTTGTGGGAAC AGGTCCTGGGGAGGAATTTA
Ube3b 6380458 GCCTGCACAGGTAACACAGA ACCAGGAGCTGCTGAGATGT
Fbxo32 110037 GGGAGGCAATGTCTGTGTTT AAGAGGTGCAGGGACTGAGA
Trim63 1740164 CGACCGAGTGCAGACGATCATCTC GTGTCAAACTTCTGACTCAGC
Ubr5 1780605 GCTGCCTTTGTGGAAAGTGT TTGCAGCCAACCACAAATAA
Asb11 2060487 TTGTGCTGAACAAGCTCCTG GAGGGTCCTGAATCATCCAA
mHPRT - CGTCGTGATTAGCGATGATG TTTTCCAAATCCTCGGCATA
Anvar et al. Skeletal Muscle 2011, 1:15
http://www.skeletalmusclejournal.com/content/1/1/15
Page 12 of 14
JV, CT, GD, AC and MS. The manuscript was drafted by SYA and VR and
written by SYA, PAC, SM and VR. PAC participated in the bioinformatics
design, coordination and data analysis. All authors read and approved the
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 December 2010 Accepted: 4 April 2011
Published: 4 April 2011
References
1. Fan X, Rouleau GA: Progress in understanding the pathogenesis of
oculopharyngeal muscular dystrophy. Can J Neurol Sci 2003, 30:8-14.
2. Blumen SC, Bouchard JP, Brais B, Carasso RL, Paleacu D, Drory VE, Chantal S,
Blumen N, Braverman I: Cognitive impairment and reduced life span of
oculopharyngeal muscular dystrophy homozygotes. Neurology 2009,
73:596-601.
3. Brais B, Xie YG, Sanson M, Morgan K, Weissenbach J, Korczyn AD,
Blumen SC, Fardeau M, Tomé FM, Bouchard JP, et al: The oculopharyngeal
muscular dystrophy locus maps to the region of the cardiac alpha and
beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol
Genet 1995, 4:429-434.
4. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM,
Lafrenière RG, Rommens JM, Uyama E, Nohira O, Blumen S, Korczyn AD,
Heutink P, Mathieu J, Duranceau A, Codère F, Fardeau M, Rouleau GA:
Short GCG expansions in the PABP2 gene cause oculopharyngeal
muscular dystrophy. Nat Genet 1998, 18:164-167.
5. Tome FM, Fardeau M: Nuclear inclusions in oculopharyngeal dystrophy.
Acta Neuropathol 1980, 49:85-87.
6. Chartier A, Benoit B, Simonelig M: A Drosophila model of oculopharyngeal
muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J 2006,
25:2253-2262.
7. Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O’Donovan DG,
Rubinsztein DC: Doxycycline attenuates and delays toxicity of the
oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat
Med 2005, 11:672-677.
8. Catoire H, Pasco MY, Abu-Baker A, Holbert S, Tourette C, Brais B,
Rouleau GA, Parker JA, Néri C: Sirtuin inhibition protects from the
polyalanine muscular dystrophy protein PABPN1. Hum Mol Genet 2008,
17:2108-2117.
9. Davies JE, Sarkar S, Rubinsztein DC: Trehalose reduces aggregate
formation and delays pathology in a transgenic mouse model of
oculopharyngeal muscular dystrophy. Hum Mol Genet 2006, 15:23-31.
10. Chartier A, Raz V, Sterrenburg E, Verrips CT, van der Maarel SM,
Simonelig M: Prevention of oculopharyngeal muscular dystrophy by
muscular expression of Llama single-chain intrabodies in vivo. Hum Mol
Genet 2009, 18:1849-1859.
11. Trollet C, Anvar SY, Venema A, Hargreaves IP, Foster K, Vignaud A, Ferry A,
Negroni E, Hourde C, Baraibar MA, ’t Hoen PA, Davies JE, Rubinsztein DC,
Heales SJ, Mouly V, van der Maarel SM, Butler-Browne G, Raz V, Dickson G:
Molecular and phenotypic characterization of a mouse model of
oculopharyngeal muscular dystrophy reveals severe muscular atrophy
restricted to fast glycolytic fibres. Hum Mol Genet 2010, 19:2191-2207.
12. Hino H, Araki K, Uyama E, Takeya M, Araki M, Yoshinobu K, Miike K,
Kawazoe Y, Maeda Y, Uchino M, Yamamura K: Myopathy phenotype in
transgenic mice expressing mutated PABPN1 as a model of
oculopharyngeal muscular dystrophy. Hum Mol Genet 2004, 13:181-190.
13. Ioannidis JP, Allison DB, Ball CA, Coulibaly I, Cui X, Culhane AC, Falchi M,
Furlanello C, Game L, Jurman G, Mangion J, Mehta T, Nitzberg M, Page GP,
Petretto E, van Noort V: Repeatability of published microarray gene
expression analyses. Nat Genet 2009, 41:149-155.
14. Smyth GK: Linear models and empirical Bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol
2004, 3:Article3.
15. Jelier R, Schuemie MJ, Veldhoven A, Dorssers LC, Jenster G, Kors JA: Anni 2.0: a
multipurpose text-mining tool for the life sciences. Genome Biol 2008, 9:R96.
16. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC: A global test
for groups of genes: testing association with a clinical outcome.
Bioinformatics 2004, 20:93-99.
17. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA:
DAVID: Database for Annotation, Visualization, and Integrated Discovery.
Genome Biol 2003, 4:3.
18. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 2009, 4:44-57.
19. Cao PR, Kim HJ, Lecker SH: Ubiquitin-protein ligases in muscle wasting.
Int J Biochem Cell Biol 2005, 37:2088-2097.
20. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA,
Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM,
DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ: Identification of
ubiquitin ligases required for skeletal muscle atrophy. Science 2001,
294:1704-1708.
21. Sandri M: Signaling in muscle atrophy and hypertrophy. Physiology
(Bethesda) 2008, 23:160-170.
22. Reyes-Turcu FE, Ventii KH, Wilkinson KD: Regulation and cellular roles of
ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009,
78:363-397.
23. Finley D: Recognition and processing of ubiquitin-protein conjugates by
the proteasome. Annu Rev Biochem 2009, 78:477-513.
24. Abu-Baker A, Messaed C, Laganiere J, Gaspar C, Brais B, Rouleau GA:
Involvement of the ubiquitin-proteasome pathway and molecular
chaperones in oculopharyngeal muscular dystrophy. Hum Mol Genet
2003, 12:2609-2623.
25. Victor M, Hayes R, Adams RD: Oculopharyngeal muscular dystrophy. A
familial disease of late life characterized by dysphagia and progressive
ptosis of the evelids. N Engl J Med 1962, 267:1267-1272.
26. Calado A, Tomé FM, Brais B, Rouleau GA, Kuhn U, Wahle E, Carmo-
Fonseca M: Nuclear inclusions in oculopharyngeal muscular dystrophy
consist of poly(A) binding protein 2 aggregates which sequester poly(A)
RNA. Hum Mol Genet 2000, 9:2321-2328.
27. Tavanez JP, Calado P, Braga J, Lafarga M, Carmo-Fonseca M: In vivo
aggregation properties of the nuclear poly(A)-binding protein PABPN1.
RNA 2005, 11:752-762.
28. Kloetzel PM, Ossendorp F: Proteasome and peptidase function in MHC-
class-I-mediated antigen presentation. Curr Opin Immunol 2004, 16:76-81.
29. Ferrington DA, Husom AD, Thompson LV: Altered proteasome structure,
function, and oxidation in aged muscle. FASEB J 2005, 19:644-646.
30. Osna NA, Clemens DL, Donohue TM Jr: Interferon gamma enhances
proteasome activity in recombinant Hep G2 cells that express
cytochrome P4502E1: modulation by ethanol. Biochem Pharmacol 2003,
66:697-710.
31. Hoeller D, Dikic I: Targeting the ubiquitin system in cancer therapy.
Nature 2009, 458:438-444.
32. Liu Z, Miers WR, Wei L, Barrett EJ: The ubiquitin-proteasome proteolytic
pathway in heart vs skeletal muscle: effects of acute diabetes. Biochem
Biophys Res Commun 2000, 276:1255-1260.
33. Combaret L, Dardevet D, Bechet D, Taillandier D, Mosoni L, Attaix D:
Skeletal muscle proteolysis in aging. Curr Opin Clin Nutr Metab Care 2009,
12:37-41.
34. Taillandier D, Combaret L, Pouch MN, Samuels SE, Bechet D, Attaix D: The
role of ubiquitin-proteasome-dependent proteolysis in the remodelling
of skeletal muscle. Proc Nutr Soc 2004, 63:357-361.
35. Ciechanover A, Brundin P: The ubiquitin proteasome system in
neurodegenerative diseases: sometimes the chicken, sometimes the
egg. Neuron 2003, 40:427-446.
36. Vignaud A, Ferry A, Huguet A, Baraibar M, Trollet C, Hyzewicz J, Butler-
Browne G, Puymirat J, Gourdon G, Furling D: Progressive skeletal muscle
weakness in transgenic mice expressing CTG expansions is associated
with the activation of the ubiquitin-proteasome pathway. Neuromuscul
Disord 2010, 20:319-325.
37. Lee CK, Klopp RG, Weindruch R, Prolla TA: Gene expression profile of
aging and its retardation by caloric restriction. Science 1999,
285:1390-1393.
38. Corbeil-Girard LP, Klein AF, Sasseville AM, Lavoie H, Dicaire MJ, Saint-
Denis A, Pagé M, Duranceau A, Codère F, Bouchard J-P, Karpati G,
Rouleau GA, Massie B, Langelier Y, Brais B: PABPN1 overexpression leads
to upregulation of genes encoding nuclear proteins that are
sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.
Neurobiol Dis 2005, 18:551-567.
Anvar et al. Skeletal Muscle 2011, 1:15
http://www.skeletalmusclejournal.com/content/1/1/15
Page 13 of 14
39. Smyth GK, Speed T: Normalization of cDNA microarray data. Methods
2003, 31:265-273.
40. Li W, Bengtson MH, Ulbrich A, Matsuda A, Reddy VA, Orth A, Chanda SK,
Batalov S, Joazeiro CA: Genome-wide and functional annotation of
human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that
regulates the organelle’s dynamics and signaling. PLoS One 2008, 3:
e1487.
41. Raz V, Carlotti F, Vermolen BJ, van der Poel E, Sloos WC, Knaan-Shanzer S,
de Vries AA, Hoeben RC, Young IT, Tanke HJ, Garini Y, Dirks RW: Changes in
lamina structure are followed by spatial reorganization of
heterochromatic regions in caspase-8-activated human mesenchymal
stem cells. J Cell Sci 2006, 119:4247-4256.
doi:10.1186/2044-5040-1-15
Cite this article as: Anvar et al.: Deregulation of the ubiquitin-
proteasome system is the predominant molecular pathology in OPMD
animal models and patients. Skeletal Muscle 2011 1:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Anvar et al. Skeletal Muscle 2011, 1:15
http://www.skeletalmusclejournal.com/content/1/1/15
Page 14 of 14
